50850-93-6 Usage
Description
Ethyl 2-amino-1,3-benzothiazole-6-carboxylate is an organic compound with the chemical formula C10H10N2O2S. It is a derivative of benzothiazole, a heterocyclic compound consisting of a benzene ring fused to a thiazole ring. The presence of an amino group and a carboxylate group in its structure makes it a versatile building block in organic synthesis.
Uses
Used in Organic Synthesis:
Ethyl 2-amino-1,3-benzothiazole-6-carboxylate is used as a synthetic intermediate for the preparation of various pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure allows for the formation of diverse chemical entities through various synthetic routes.
Used in Pharmaceutical Industry:
Ethyl 2-amino-1,3-benzothiazole-6-carboxylate is used as a key building block in the synthesis of drugs targeting various therapeutic areas, such as cardiovascular, neurological, and oncological diseases. Its presence in the molecular structure can impart specific biological activities and improve the pharmacokinetic properties of the final drug candidates.
Used in Agrochemical Industry:
Ethyl 2-amino-1,3-benzothiazole-6-carboxylate is used as a precursor in the development of agrochemicals, such as pesticides and herbicides. Its incorporation into the molecular structure can enhance the effectiveness of these chemicals in controlling pests and weeds, thereby improving crop yields and quality.
Used in Dye and Pigment Industry:
Ethyl 2-amino-1,3-benzothiazole-6-carboxylate is used as a starting material for the synthesis of dyes and pigments with specific color properties and stability. Its unique structure allows for the development of novel dyes and pigments with improved performance in various applications, such as textiles, plastics, and printing inks.
Check Digit Verification of cas no
The CAS Registry Mumber 50850-93-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,8,5 and 0 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 50850-93:
(7*5)+(6*0)+(5*8)+(4*5)+(3*0)+(2*9)+(1*3)=116
116 % 10 = 6
So 50850-93-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H10N2O2S/c1-2-14-9(13)6-3-4-7-8(5-6)15-10(11)12-7/h3-5H,2H2,1H3,(H2,11,12)
50850-93-6Relevant articles and documents
Tautomeric enhancement of the hyperpolarizability in new acridine-benzothiazolylamine based NLO chromophores
Molinos-Gómez, Alberto,Vidal, Xavier,Maymó, Marc,Velasco, Dolors,Martorell, Jordi,López-Calahorra, Francisco
, p. 9075 - 9081 (2005)
The second order NLO response of a new family of acridine-based chromophores is greatly enhanced due to the presence of a tautomeric minor form with high charge-transfer capabilities.
Visible-light-initiated malic acid-promoted cascade coupling/cyclization of aromatic amines and KSCN to 2-aminobenzothiazoles without photocatalyst
He, Wei-Bao,Gao, Lan-Qing,Chen, Xin-Jie,Wu, Zhi-Lin,Huang, Ying,Cao, Zhong,Xu, Xin-Hua,He, Wei-Min
supporting information, p. 1895 - 1898 (2020/02/27)
By using ambient air as the oxidant and malic acid as the promoter, a practical method for the preparation of 2-aminobenzothiazoles through visible-light-initiated cascade reaction of aromatic amines and KSCN in eco-friendly bis(methoxypropy)ether under metal-, hazardous additive-, photocatalyst-free conditions was established.
FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
-
Paragraph 0062; 0063, (2018/11/27)
The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.